

Effective Date: 9/2018
Revised: 12/2019
Reviewed: 9/2018, 12/2019
Scope: Medicaid

## **SUBLOCADE (buprenorphine extended-release) INJECTION**

### **POLICY**

#### **I. CRITERIA FOR INITIAL APPROVAL**

##### **Moderate to severe opioid use disorder**

Authorization of 6 months may be granted for treatment of moderate to severe opioid use disorder in members 18 years of age or older when all of the following criteria are met:

- A. Member has initiated therapy with transmucosal buprenorphine containing product (delivering the equivalent of 8-24mg of buprenorphine daily) over a minimum of 7 day period and is stable with clinically controlled cravings and withdrawal symptoms.
- B. Member is part of a complete treatment program that includes counseling and psychosocial support.
- C. Member is not receiving other opioids during therapy with Sublocade.
- D. Rationale is provided to support the member's inability to continue to use oral formulations of buprenorphine.
- E. The dose of Sublocade does not exceed 300mg a month.

#### **II. CONTINUATION OF THERAPY**

Authorization of 12 months may be granted for treatment of moderate to severe opioid use disorder in patients when all of the following criteria are met:

- A. Member continues to meet the initial criteria in section I.
- B. Member is tolerating treatment.
- C. Member has shown a decrease in signs of opioid dependence relapse.